Impact of Direct Acting Antivirals Uptake in Controlling Hepatitis C Epidemic and Modeling Interventions for Hepatitis C Elimination Among HIV-infected Persons in San Diego
试验速览
- 阶段
- 不适用
- 入组人数
- 450
- 试验地点
- 1
- 主要终点
- Annual proportion of HIV-infected patients who initiate direct acting antivirals
研究概览
简要总结
A retrospective and prospective study among people living with HIV (PLWH) that assesses hepatitis C (HCV) treatment uptake during periods before and after direct acting antivirals (DAA) introduction, and its impact on the HCV epidemic among PLWH.
详细描述
A study that aims to quantify the state of DAA uptake and its impact on the HCV epidemic among PLWH in San Diego, and to characterize negative predictors of DAA treatment uptake among PLWH in San Diego. Retrospective and prospective data from UCSD Owen Clinic will be utilized to calculate HCV prevalence, primary incidence, and reinfection incidence. Using mathematical epidemic models, the study will assess levels of existing and scaled-up interventions necessary for HCV elimination from PLWH in San Diego.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Any adult (≥ 18 years) HIV-infected patient attending the UCSD Owen Clinic
- •With history of acute or chronic HCV infection defined as having a detectable HCV viral load with or without a positive HCV antibody
排除标准
- •With no history of or current HCV infection defined as having a negative HCV antibody from 2008 to 2020
结局指标
主要结局
Annual proportion of HIV-infected patients who initiate direct acting antivirals
时间窗: 2014-2020
次要结局
- Annual HCV chronic prevalence, primary incidence, and reinfection incidence among HIV-infected patients(2008-2020)
- Annual proportion of PLWH co-infected with HCV who are treatment naïve, previously treated with no sustained virologic response (SVR), or re-infected post-SVR(2008-2020)
研究者
Edward Cachay, MD, MAS
Associate Professor of Clinical Medicine
University of California, San Diego